Survey
Quarterly Survey: mCRPC and Pluvicto Lutetium-177 PSMA Therapy April 2023
Ticker(s): NVSSurvey results include 20 Oncologists.
How many patients with Advanced Metastatic Prostate Cancer are in your practice?
Do you currently prescribe or have your prescribed Pluvicto (Lutetium-177 vipivotide tetraxetan)?
How would you best describe your practice?
How many of your patients do you consider eligible for Pluvicto (Lutetium-177 vipivotide tetraxetan)?
How many of your patients do you prescribe Pluvicto today?
How many of your patients started Pluvicto in the last 90 days?
How many of your patients discontinued Pluvicto in the last 90 days?
How many patients do you expect to prescribe Pluvicto in the next 90 days (cumulative)?
How do you expect usage of Pluvicto in your patients to change moving forward?
- Increase
- Decrease
- Stay the same
In response to you answer above: why is that?
How would you rate Pluvicto on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
What changes, if any, have you noticed with payor reimbursement and insurance for prostate cancer treatments?
Please elaborate on your view of Pluvicto.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
